Multiple Myeloma Market

DelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.


The MM market report provides current treatment practices, emerging drugs, MM market share of the individual therapies, current and forecasted MM market size from 2017 to 2030 segmented by eight major markets. The Report also covers current MM treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • China

Study Period: 2017–2030

Multiple Myeloma (MM): Disease Understanding and Treatment Algorithm

Multiple Myeloma Overview

According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74. Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.


Multiple Myeloma Diagnosis

Multiple myeloma is often diagnosed based on tests, the patient’s symptoms and the doctor’s physical exam of the patient. A diagnosis of multiple myeloma requires either:


1. A plasma cell tumor (proven by biopsy) or at least 10% plasma cells in the bone marrow

2. At least one of the following:

  • High blood calcium level
  • Poor kidney function
  • Low red blood cell counts (anemia)
  • Holes in the bones from a tumor found on imaging studies (CT, MRI, PET scan)
  • Increase in one type of light chain in the blood so that one type is 100 times more common than the other
  • 60% or more plasma cells in the bone marrow


Multiple Myeloma Treatment

The main treatment options include stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy. Also, the survival of patients with myeloma has improved due to the development and approval of new treatments. MM treatment strategies have also evolved with the emergence of new therapies with a novel mechanism of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets.

Multiple Myeloma (MM) Epidemiology

The Multiple Myeloma epidemiology division provide the insights about historical and current Multiple Myeloma patient pool and forecasted trend for each eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The MM epidemiology division provides insights about historical and current patient pool and forecasted trends for each eight major countries. The Multiple Myeloma epidemiology data are studied through Multiple Myeloma possible division to give a better understanding of the Disease scenario in the 8MM.


The disease epidemiology covered in the report provides historical as well as forecasted Multiple Myeloma epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of Multiple Myeloma, Total Incident Cases of Multiple Myeloma Segmented by Gender, Total Diagnosed cases of Multiple Myeloma by Age Distribution, Total Cases of Multiple Myeloma by Line of Treatment] scenario of Multiple Myeloma in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030

Country Wise- Multiple Myeloma Epidemiology

  • In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 8MM. The United States, in 2020, accounted for 32,270 cases (the highest number), which will probably rise by the year 2030. Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma in the year 2020, was in Germany. In China, the total number of incident cases of Multiple Myeloma was 21,116 in 2020, and this number is expected to rise throughout the forecast period.
  • The overall number of symptomatic cases of Multiple Myeloma in the 8MM was 80,715, and these cases are expected to rise by 2030.
  • Males are more likely to develop Multiple Myeloma than females (about 55 percent of cases). When it comes to age-specific Multiple Myeloma cases, the age group 65–74 years has by far the most, followed by 75–84 years and 55–64 years.
  • In the 8MM, the total cases of Multiple Myeloma by treatment line were 23,581 cases for frontline transplant-eligible patients, 49,699 cases for frontline transplant-ineligible patients, 44,955 cases for second-line patients, 23,498 cases for third-line patients, and 10,236 cases for fourth-line plus patients, in the year 2020.

Multiple Myeloma Drug Chapters

Drug chapter segment of the Multiple Myeloma report encloses the detailed analysis of Multiple Myeloma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Multiple Myeloma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Multiple Myeloma Marketed Drugs


Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline

GlaxoSmithKline’s lead candidate, Belantamab Mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with an afucosylated, humanized IgG1 anti-BCMA monoclonal antibody conjugated by a protease-resistant maleimidocaproyl linker to a microtubule-disrupting agent, monomethyl auristatin F (MMAF). The drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa. It was approved by UDFDA and the European Commission in August 2020. This drug has received orphan drug designation from the EMA and the US FDA for multiple myeloma. Apart from this, the EMA and the US FDA have also granted PRIME designation and Breakthrough Therapy designation, respectively.


Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio

Abecma (ide-cel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy co-developed, and co-promoted by Bristol Myers Squibb and Bluebird bio for the treatment of adult patients with multiple myeloma who have received at least three prior therapies. In March 2021, the USFDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.


Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB

Pepaxto is a first-in-class anti-cancer peptide-drug conjugate that rapidly produces an alkylating payload into tumor cells. It is promptly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In February 2021, the USFDA approved Pepaxto in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.


Sarclisa (Isatuximab): Sanofi

Sarclisa— a product of Sanofi is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells. It is manufactured and designed to initiate programmed tumor cell death (apoptosis) and immunomodulatory activity. In December 2017, Isatuximab received Orphan Designation for the treatment of patients with Relapsed or Refractory Multiple Myeloma by the US FDA and EMA.


Xpovio (Selinexor): Karyopharm

Karyopharm’ potential candidate Selinexor is an oral, first-in-class, selective inhibitor of nuclear export also known as SINE, compound. It has been approved by the US FDA in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. In April 2021, EMA validated the Company's Type II Variation MAA, which seeks to expand the currently authorized indication for Nexpovio in the European Union to include, in combination with Velcade (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Validation of the application confirms the submission is complete to begin the EMA's review process.


Darzalex (Daratumumab): Janssen Biotech

Darzalex (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. Darzalex is not chemotherapy. It is a human IgG1k monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. In November 2015, Darzalex first received the US FDA approval as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent. Recently, in April 2020, the US FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. Darzalex Faspro is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.

Products detail in the report…


Multiple Myeloma Emerging Drugs


Venetoclax (ABT-199): AbbVie and Roche

Venetoclax (Venclexta, Venclyxto) is an oral B-cell lymphoma-2 (BCL-2) inhibitor developed by AbbVie and Genentech. It is used for the treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) and in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2. In March 2019, the US FDA placed a partial clinical hold on Venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase III trial (NCT02755597). In June 2019, the US FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol (Myeloma Positive for the t(11;14) Genetic Abnormality), including new risk mitigation measures, protocol-specified guidelines, and updated futility criteria (AbbVie News Center, 2019).


Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M): Janssen Biotech/Nanjing Legend Biotech

Ciltacabtagene Autoleucel is currently being investigated for the treatment of patients with multiple myeloma who have received at least three prior regimens, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and have documented disease progression within 12 months of starting the most recent therapy, or are double refractory to an immunomodulatory drug and a proteasome inhibitor. This product is being evaluated under licensing and collaboration agreements between Janssen and Legend Biotech. In the first quarter of 2021, the rolling submission of a Biologics License Application (BLA) to the USFDA was completed by Janssen, for cilta-cel, for the treatment of adults with relapsed or refractory multiple myeloma. Additionally, in April 2021, the company has also submitted the MAA to the EMA for cilta-cel (Legend Biotech, 2021b).


REGN5458: Regeneron Pharmaceuticals

REGN5458 is a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. In December 2019, the company presented the results at the American Society of Hematology (ASH) Annual Meeting. Currently, REGN5458 monotherapy is being investigated in an open-label, Phase I/II (NCT03761108) dose-escalation trial in patients with relapsed or refractory multiple myeloma who are at least triple refractory to existing therapeutic options, including proteasome inhibitors, immunomodulatory drugs, and CD38 antibody treatments.


Iberdomide (CC-220): Bristol-Myers Squibb/Celgene

Iberdomide is an investigational cereblon E3 ligase modulator compound with enhanced tumoricidal and Immunostimulatory activities that induces degradation of transcription factors Aiolos and Ikaros, thereby inhibiting the growth of myeloma cells in vitro. In pre-clinical models, iberdomide has demonstrated the ability to destroy tumor cells, stimulate an immune response, overcome resistance to immunomodulatory drugs, and synergize with dexamethasone, daratumumab, and bortezomib (Celgene Corporation, 2019). In December 2018, the US FDA has granted orphan drug designation to iberdomide for the treatment of multiple myeloma.

Products detail in the report…

Multiple Myeloma Market Outlook

Key Findings

According to DelveInsight, the Multiple Myeloma market size in the 8MM is expected to change at a CAGR of 4.3% during the study period (2017–2030). In the total market size of Multiple Myeloma in the 8MM, the United States accounted for the highest market size in 2020 followed by Japan, Germany, and France.


The United States Market Outlook

In the United States, the total market size of Multiple Myeloma is expected to increase at a CAGR of 4.0% during the study period (2017–2030).


EU-5 Countries: Market Outlook

In EU-5 countries, the total market size of Multiple Myeloma is expected to increase at a CAGR of 4.8% during the study period (2017–2030).


Japan Market Outlook

In Japan, the total market size of Multiple Myeloma is expected to increase at a CAGR of 3.9% during the study period (2017–2030).


China Market Outlook

In China, the total market size of Multiple Myeloma is expected to increase at a CAGR of 6.2% during the study period (2017–2030).

Multiple Myeloma Pipeline Development Activities

The drugs which are in pipeline include:

  • Venetoclax (ABT-199): AbbVie and Roche
  • JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
  • Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.
  • Cetrelimab (JNJ-63723283): Janssen Research & Development
  • REGN5458: Regeneron Pharmaceuticals
  • Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma
  • Chidamide (Epidaza): Chipscreen Biosciences
  • Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
  • Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
  • Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)
  • CLR 131 (131-CLR1404): Cellectar Biosciences
  • BL-8040: BioLineRx
  • GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
  • ECT-001: ExCellThera
  • TAK-079: Takeda
  • GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)
  • P-BCMA-101 CAR-T cells: Poseida Therapeutics
  • Opdivo (Nivolumab): Bristol-Myers Squibb
  • PBCAR269A: Precision BioSciences
  • MP0250: Molecular Partners AG
  • Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical
  • Descartes-11: Cartesian Therapeutics
  • Imfinzi (Durvalumab): AstraZeneca
  • Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson


Products detail will be provided in the report…


Pipeline Development Activities

Key Points

  • In June 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the USFDA has granted Breakthrough Therapy Designation for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, a bispecific antibody targeting both BCMA and CD3 receptors, follows a PRIME designation from the EMA received earlier this year.
  • In May 2021, Oncopeptides has announced positive results from the OCEAN study, which compared the effectiveness and safety of melflufen with pomalidomide in patients with relapsed refractory multiple myeloma. The phase III OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
  • In May 2021, the USFDA granted priority review to the Biologics License Applications (BLA) for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma. The regulatory agency is expected to decide on the application by November 29, 2021, under the Prescription Drug User Fee Act.
  • In April 2021, Legend Biotech announced the submission of a MAA to the EMA seeking approval of ciltacabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma. The EMA’s Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment for this MAA.

Multiple Myeloma Drugs Uptake

Analyst Opinion

Among the IMid’s agent lenalidomide (Revlimid) dominates the Multiple Myeloma market in the 8MM, where it is included in all lines of Multiple Myeloma therapy either as monotherapy or in combination with other drugs. According to a settlement deal between Celgene and Natco Pharma, a limited generic entry will begin in March 2022 for this candidate, and from January 31, 2026, generic entry will be permitted without volume limitation in the United States. Despite the loss of patent exclusivity in important markets and the approval of other prospective pipeline candidates, lenalidomide is expected to have a significant presence in 2030. Among emerging therapies, Ciltacabtagene autoleucel (JNJ-68284528) from Janssen Biotech/Nanjing Legend Biotech is expected to give tough competition to Idecabtagene Vicleucel.

Access and Reimbursement Scenario in Multiple Myeloma Therapies

  • In March 2019, the Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) plus Velcade (bortezomib) and dexamethasone (DVd) for use within the Cancer Drugs Fund (CDF), as an option for treating relapsed multiple myeloma in people who have had one previous treatment. Patients at the second line will now have access to a treatment combination, which NICE accepts had a ‘clinically important and statistically significant effect on progression-free survival.
  • With effect from August 2020, the Medicaid and NC Health Choice programs cover belantamab mafodotin-blmf for injection, for intravenous use (Blenrep) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code. Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (NCDHHS, 2020).

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Multiple Myeloma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Multiple Myeloma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Multiple Myeloma Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Multiple Myeloma, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Multiple Myeloma epidemiology and treatment in the 8MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Multiple Myeloma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Multiple Myeloma market; historical and forecasted is included in the report, covering drug outreach in the 8MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Multiple Myeloma market.

Report Highlights

  • In the coming years, Multiple Myeloma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Multiple Myeloma. Launch of emerging therapies, will significantly impact the Multiple Myeloma market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Multiple Myeloma.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Multiple Myeloma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Multiple Myeloma Pipeline Analysis
  • Multiple Myeloma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Multiple Myeloma Report Key Strengths

  • 10 Years Forecast
  • 8MM Coverage
  • Multiple Myeloma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Multiple Myeloma Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Multiple Myeloma Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Multiple Myeloma total market Size as well as market size by therapies across the 8MM during the study period (2017–2030)?
  • What are the key findings pertaining to the market across the 8MM and which country will have the largest Multiple Myeloma market size during the study period (2017–2030)?
  • At what CAGR, the Multiple Myeloma market is expected to grow in the 8MM during the study period (2017–2030)?
  • What would be the Multiple Myeloma market outlook across the 8MM during the study period (2017–2030)?
  • What would be the Multiple Myeloma market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • Multiple Myeloma patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Multiple Myeloma market?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Multiple Myeloma?
  • What is the historical Multiple Myeloma patient pool in eight major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan and China?
  • What would be the forecasted patient pool of Multiple Myeloma in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan and China?
  • What will be the growth opportunities in the 8MM with respect to the patient population pertaining to Multiple Myeloma?
  • Out of all the 8MM countries, which country would have the highest Incident population of Multiple Myeloma during the study period (2017–2030)?
  • At what CAGR the population is expected to grow in the 8MM during the study period (2017–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Multiple Myeloma?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Multiple Myeloma along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Multiple Myeloma in the US, Europe Japan and China?
  • What are the Multiple Myeloma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Multiple Myeloma?
  • How many therapies are developed by each company for the treatment of Multiple Myeloma?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Multiple Myeloma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple Myeloma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Multiple Myeloma and their status?
  • What are the key designations that have been granted for the emerging therapies for Multiple Myeloma?
  • What are the global historical and forecasted market of Multiple Myeloma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma market.
  • To understand the future market competition in the Multiple Myeloma market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) Japan and China.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma market.
  • To understand the future market competition in the Multiple Myeloma market.

1. Key Insights

2. Report Introduction

3. Multiple Myeloma Market Overview at a Glance

3.1. Market Share (%) Distribution of Multiple Myeloma in 2017: By Country

3.2. Market Share (%) Distribution of Multiple Myeloma in 2030: By Country

3.3. Market Share (%) Distribution of Multiple Myeloma in 2017: By Class

3.4. Market Share (%) Distribution of Multiple Myeloma in 2017: By Class

4. Executive Summary of Multiple Myeloma

4.1. Key Events

5. Epidemiology and Market Forecast Flow

6. Disease Background and Overview

6.1. Introduction

6.2. Multiple Myeloma features

6.2.1. Low blood counts

6.2.2. Bone and calcium problems

6.2.3. Infections

6.2.4. Kidney problems

6.3. Causes of Multiple Myeloma

6.4. Risk factors of Multiple Myeloma

6.5. Signs and Symptoms

6.5.1. Bone Problems

6.5.2. Low blood counts

6.5.3. High blood levels of calcium

6.5.4. Nervous system symptoms

6.5.5. Kidney Problems

6.5.6. Infections

6.6. Pathogenesis of Multiple Myeloma

6.6.1. Molecular mechanisms underlying the progression of multiple myeloma

6.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor

6.7. Pathophysiology of Multiple Myeloma

6.8. Patient-related risk factors

6.9. Biomarkers for Multiple Myeloma

6.9.1. Serum M-protein and light chains as biomarkers

6.9.2. Potential proteomic biomarkers

6.9.3. Cytogenetic biomarkers in multiple myeloma

7. Diagnosis of Multiple Myeloma

7.1. Lab tests

7.2. Biopsies

7.3. Imaging tests

7.4. Stages of Multiple Myeloma

8. Treatment

8.1. Drug therapy for Multiple Myeloma

8.1.1. Chemotherapy

8.1.2. Corticosteroids (steroids)

8.1.3. Immunomodulating agents

8.1.4. Proteasome inhibitors

8.1.5. Histone deacetylase (HDAC) inhibitors

8.1.6. Monoclonal antibodies

8.1.7. Nuclear export inhibitor

8.1.8. Using the drugs together or in combination to treat multiple myeloma

8.1.9. Bisphosphonates for bone disease

8.2. Radiation Therapy for Multiple Myeloma

8.3. Surgery for Multiple Myeloma

8.4. Stem Cell Transplant for Multiple Myeloma

8.4.1. Autologous transplants

8.4.2. Allogeneic transplants

8.5. Supportive Treatments for Patients with Multiple Myeloma

8.5.1. Intravenous immunoglobulin (IVIG)

8.5.2. Treatment for low blood cell counts

8.5.3. Plasmapheresis

8.6. Treatment Options for Multiple Myeloma by Stage

8.6.1. Solitary plasmacytomas

8.6.2. Smoldering multiple myeloma

8.6.3. Active (symptomatic) myeloma

8.7. Factors influencing the choice of therapy at relapse

8.8. Treatment Guidelines for Multiple Myeloma

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Assumptions and Rationale

9.3. Epidemiology Scenario: 8MM

9.3.1. Total Incident Cases of Multiple Myeloma in the 8MM

9.3.2. Total Symptomatic Cases of Multiple Myeloma in the 8MM

9.3.3. Gender-specific cases of Multiple Myeloma in the 8MM

9.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM

9.3.5. Cases of Multiple Myeloma by Treatment Line in the 8MM

9.4. The United States Epidemiology

9.4.1. Total Incident Cases of Multiple Myeloma in the United States

9.4.2. Total Symptomatic Cases of Multiple Myeloma in the United States

9.4.3. Gender-specific cases of Multiple Myeloma in the United States

9.4.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United States

9.4.5. Cases of Multiple Myeloma by Treatment Line in the United States

9.5. EU-5 Epidemiology

9.6. Germany

9.6.1. Total Incident Cases of Multiple Myeloma in Germany

9.6.2. Total Symptomatic Cases of Multiple Myeloma in Germany

9.6.3. Gender-specific cases of Multiple Myeloma in Germany

9.6.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Germany

9.6.5. Cases of Multiple Myeloma by Treatment Line in Germany

9.7. France

9.7.1. Total Incident Cases of Multiple Myeloma in France

9.7.2. Total Symptomatic Cases of Multiple Myeloma in France

9.7.3. Gender-specific cases of Multiple Myeloma in France

9.7.4. Diagnosed cases of Multiple Myeloma by Age Distribution in France

9.7.5. Cases of Multiple Myeloma by Treatment Line in France

9.8. Italy

9.8.1. Total Incident Cases of Multiple Myeloma in Italy

9.8.2. Total Symptomatic Cases of Multiple Myeloma in Italy

9.8.3. Gender-specific cases of Multiple Myeloma in Italy

9.8.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Italy

9.8.5. Cases of Multiple Myeloma by Treatment Line in Italy

9.9. Spain

9.9.1. Total Incident Cases of Multiple Myeloma in Spain

9.9.2. Total Symptomatic Cases of Multiple Myeloma in Spain

9.9.3. Gender-specific cases of Multiple Myeloma in Spain

9.9.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Spain

9.9.5. Cases of Multiple Myeloma by Treatment Line in Spain

9.10.The United Kingdom

9.10.1. Total Incident Cases of Multiple Myeloma in the United Kingdom

9.10.2. Total Symptomatic Cases of Multiple Myeloma in the United Kingdom

9.10.3. Gender-specific cases of Multiple Myeloma in the United Kingdom

9.10.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom

9.10.5. Cases of Multiple Myeloma by Treatment Line in the United Kingdom

9.11.Japan Epidemiology

9.11.1. Total Incident Cases of Multiple Myeloma in Japan

9.11.2. Total Symptomatic Cases of Multiple Myeloma in Japan

9.11.3. Gender-specific cases of Multiple Myeloma in Japan

9.11.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Japan

9.11.5. Cases of Multiple Myeloma by Treatment Line in Japan

9.12. China Epidemiology

9.12.1. Total Incident Cases of Multiple Myeloma in China

9.12.2. Total Symptomatic Cases of Multiple Myeloma in China

9.12.3. Gender-specific cases of Multiple Myeloma in China

9.12.4. Diagnosed cases of Multiple Myeloma by Age Distribution in China

9.12.5. Cases of Multiple Myeloma by Treatment Line in China

10. Patient Journey

11. Key Endpoints in Multiple Myeloma

12. Marketed Therapies

12.1. Key Cross of Marketed Therapies

12.2. Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline

12.2.1. Product Description

12.2.2. Regulatory milestones

12.2.3. Other Developmental Activities

12.2.4. Pivotal Clinical Trial

12.2.5. Clinical Development

12.2.6. Safety and Efficacy

12.3. Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio

12.3.1. Product Description

12.3.2. Regulatory Milestones

12.3.3. Other Developmental Activities

12.3.4. Pivotal Clinical Trial

12.3.5. Clinical Development

12.3.6. Safety and Efficacy

12.4. Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB

12.4.1. Product Description

12.4.2. Regulatory milestones

12.4.3. Other Developmental Activities

12.4.4. Pivotal Clinical Trial

12.4.5. Clinical Development

12.4.6. Safety and Efficacy

12.5. Farydak (Panobinostat): Secura Bio

12.5.1. Product Description

12.5.2. Regulatory Milestones

12.5.3. Other Developmental Activities

12.5.4. Pivotal Clinical Trials

12.5.5. Ongoing Current Pipeline Activity

12.6. Kyprolis (Carfilzomib): Amgen (Onyx therapeutics)

12.6.1. Product Description

12.6.2. Regulatory Milestones

12.6.3. Other Developmental Activities

12.6.4. Pivotal Clinical Trials

12.6.5. Ongoing Current Pipeline Activity

12.7. Ninlaro (Ixazomib): Takeda Pharmaceutical (Millennium Pharmaceuticals)

12.7.1. Product Description

12.7.2. Regulatory Milestones

12.7.3. Other Developmental Activities

12.7.4. Pivotal Clinical Trials

12.7.5. Ongoing Current Pipeline Activity

12.7.6. Safety and Efficacy

12.8. Sarclisa (Isatuximab): Sanofi

12.8.1. Product Description

12.8.2. Regulatory Milestones

12.8.3. Other Developmental Activities

12.8.4. Pivotal Clinical Trial

12.8.5. Ongoing Clinical Pipeline Activity

12.9. Xpovio (Selinexor; Nexpovio): Karyopharm Therapeutics

12.9.1. Product Description

12.9.2. Regulatory Milestones

12.9.3. Other Developmental Activities

12.9.4. Pivotal Clinical Trial

12.9.5. Ongoing Clinical Pipeline Activity

12.10. Darzalex (Daratumumab): Janssen Biotech

12.10.1. Product Description

12.10.2. Regulatory Milestones

12.10.3. Other Developmental Activities

12.10.4. Pivotal Clinical Trial

12.10.5. Ongoing Pipeline Activity

12.10.6. Safety and Efficacy

12.11. Empliciti (Elotuzumab): Bristol Myers Squibb/AbbVie

12.11.1. Product Description

12.11.2. Regulatory Milestones

12.11.3. Other Developmental Activities

12.11.4. Pivotal Clinical Trials

12.11.5. Ongoing Clinical Pipeline Activity

12.12. Velcade (Bortezomib): Takeda Pharmaceutical/Janssen Pharmaceutical

12.12.1. Product Description

12.12.2. Regulatory Milestones

12.12.3. Other Developmental Activities

12.12.4. Pivotal Clinical Trial

12.13. Pomalyst/Imnovid (Pomalidomide): Bristol-Myers Squibb Company (Celgene)

12.13.1. Product Description

12.13.2. Regulatory Milestones

12.13.3. Other Developmental Activities

12.13.4. Pivotal Clinical Trials

12.13.5. Ongoing Current Pipeline Activity

12.14. Revlimid (Lenalidomide): Celgene (BMS)

12.14.1. Product Description

12.14.2. Regulatory Milestones

12.14.3. Other Developmental Activities

12.14.4. Pivotal Clinical Trials

13. Emerging Therapies

13.1. Iberdomide (CC-220): Bristol-Myers Squibb/Celgene

13.1.1. Product Description

13.1.2. Other Developmental Activities

13.1.3. Clinical Development

13.1.4. Safety and Efficacy

13.2. Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics

13.2.1. Product Description

13.2.2. Clinical Development

13.3. Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)

13.3.1. Product Description

13.3.2. Other developmental activities

13.3.3. Clinical development

13.3.4. Safety and Efficacy

13.4. CLR 131 (131-CLR1404): Cellectar Biosciences

13.4.1. Product description

13.4.2. Other developmental activities

13.4.3. Clinical development

13.4.4. Safety and Efficacy

13.5. Motixafortide (BL-8040): BioLineRx

13.5.1. Product description

13.5.2. Other developmental activities

13.5.3. Clinical development

13.5.4. Safety and Efficacy

13.6. GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech

13.6.1. Product description

13.6.2. Other developmental activities

13.6.3. Clinical development

13.6.4. Safety and Efficacy

13.7. ECT-001: ExCellThera

13.7.1. Product Description

13.7.2. Other Developmental Activities

13.7.3. Clinical development

13.8. JNJ-7957 (JNJ-64007957, Teclistamab): Janssen Pharmaceutical

13.8.1. Product Description

13.8.2. Other Developmental Activities

13.8.3. Clinical Development

13.8.4. Safety and Efficacy

13.9. PBCAR269A: Precision BioSciences

13.9.1. Product Description

13.9.2. Other Developmental Activities

13.9.3. Clinical Development

13.10. TAK-079: Takeda

13.10.1. Product description

13.10.2. Other Developmental Activities

13.10.3. Clinical Development

13.10.4. Safety and Efficacy

13.11. GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)

13.11.1. Product Description

13.11.2. Other Developmental Activities

13.11.3. Clinical Development

13.12. P-BCMA-101 CAR-T cells: Poseida Therapeutics

13.12.1. Product Description

13.12.2. Other Developmental Activities

13.12.3. Clinical Development

13.12.4. Safety and Efficacy

13.13. MP0250: Molecular Partners AG

13.13.1. Product Description

13.13.2. Other Developmental Activities

13.13.3. Clinical Development

13.13.4. Safety and Efficacy

13.14. Chidamide (Epidaza): Chipscreen Biosciences

13.14.1. Product Description

13.14.2. Other Developmental Activities

13.14.3. Clinical Development

13.15. Venetoclax (ABT-199): AbbVie/Genentech (Roche)

13.15.1. Product Description

13.15.2. Other Developmental Activities

13.15.3. Clinical Development

13.15.4. Safety and Efficacy

13.16. Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528): Janssen Biotech/Nanjing Legend Biotech

13.16.1. Product Description

13.16.2. Other Developmental Activities

13.16.3. Clinical Development

13.16.4. Safety and Efficacy

13.17. Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.

13.17.1. Product Description

13.17.2. Other Developmental Activities

13.17.3. Clinical Development

13.17.4. Safety and Efficacy

13.18.Cetrelimab (JNJ-63723283): Janssen

13.18.1. Product Description

13.18.2. Clinical Development

13.18.3. Safety and Efficacy

13.19. REGN5458: Regeneron Pharmaceuticals

13.19.1. Product Description

13.19.2. Other Developmental Activities

13.19.3. Clinical Development

13.19.4. Safety and Efficacy

13.20. Opdivo (Nivolumab): Bristol-Myers Squibb

13.20.1. Product Description

13.20.2. Other Developmental Activities

13.20.3. Clinical Development

13.20.4. Safety and Efficacy

13.21. Descartes-11: Cartesian Therapeutics

13.21.1. Product Description

13.21.2. Other Developmental Activities

13.21.3. Clinical Development

13.22. Imfinzi (Durvalumab): AstraZeneca

13.22.1. Product Description

13.22.2. Other Developmental Activities

13.22.3. Clinical Development

13.22.4. Safety and Efficacy

13.23. Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson

13.23.1. Product Description

13.23.2. Other Developmental Activities

13.23.3. Clinical Development

13.23.4. Safety and Efficacy

13.24. MOR202 (Felzartamab; TJ-202): MorphoSys AG/I-Mab Biopharma

13.24.1. Product Description

13.24.2. Other Developmental Activities

13.24.3. Clinical Development

13.24.4. Safety and Efficacy

14. Multiple Myeloma: Eight Major Market Analysis

14.1. Key Findings

14.2. Market Outlook

14.3. China Market Outlook

14.4. Eight Major Market Size

14.4.1. Total Market size of Multiple Myeloma in the 8MM

14.4.2. Total Market size of Multiple Myeloma by Therapies in the 8MM

14.5. The United States Market Size

14.5.1. Total Market size of Multiple Myeloma in the United States

14.6. EU-5 Market Size

14.7. Germany

14.7.1. Total Market size of Multiple Myeloma in Germany

14.8. France

14.8.1. Total Market size of Multiple Myeloma in France

14.9. Italy

14.9.1. Total Market size of Multiple Myeloma in Italy

14.10. Spain

14.10.1. Total Market size of Multiple Myeloma in Spain

14.11. The United Kingdom

14.11.1. Total Market size of Multiple Myeloma in the United Kingdom

14.12. Japan Market Size

14.12.1. Total Market size of Multiple Myeloma in Japan

14.13. China Market Size

14.13.1. The total Market size of Multiple Myeloma in China

15.  Market Access and Reimbursement of Multiple Myeloma Therapies

15.1. European Market Access Challenges for Relapsed Refractory Multiple Myeloma Triplet Therapies

15.2. IQWIG AND GABA ASSESSMENT

15.3. The Institute for Clinical and Economic Review (ICER)

15.4. NC Medicaid Division of Health Benefits

15.5. Medicare Review on High-Cost CAR T-Cell Therapy

15.6. China Scenario

15.7. Patient Assistance Program

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Unmet Needs

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of Multiple Myeloma; Market, Epidemiology, and Key Events (2017–2030)

Table 2: Cytogenetic Abnormalities on Clinical Course and Prognosis in Multiple Myeloma

Table 3: The Revised International Staging System

Table 4: International Myeloma Working Group (IMWG) Diagnostic Criteria for Multiple Myeloma and Related Plasma Cell Disorders

Table 5: Recommendations for the use of ¹⁸F-FDG PET/CT in patients with multiple myeloma and other plasma cell disorders

Table 6: Guidelines for the first-line treatment of multiple myeloma

Table 7: Recommendations for the management of relapsed or refractory multiple myeloma

Table 8: Total Incident Cases of Multiple Myeloma in the 8MM (2017–2030)

Table 9: Total Symptomatic Cases of Multiple Myeloma in the 8MM (2017–2030)

Table 10: Gender-specific cases of Multiple Myeloma in the 8MM (2017–2030)

Table 11: Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017–2030)

Table 12: Cases of Multiple Myeloma by Treatment Line in the 8MM (2017–2030)

Table 13: Total Incident Cases of Multiple Myeloma in the United States (2017–2030)

Table 14: Total Symptomatic Cases of Multiple Myeloma in the United States (2017–2030)

Table 15: Gender-specific cases of Multiple Myeloma in the United States (2017–2030)

Table 16: Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017–2030)

Table 17: Cases of Multiple Myeloma by Treatment Line in the United States (2017–2030)

Table 18: Total Incident Cases of Multiple Myeloma in Germany (2017–2030)

Table 19: Total Symptomatic Cases of Multiple Myeloma in Germany (2017–2030)

Table 20: Gender-specific cases of Multiple Myeloma in Germany (2017–2030)

Table 21: Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017–2030)

Table 22: Cases of Multiple Myeloma by Treatment Line in Germany (2017–2030)

Table 23: Total Incident Cases of Multiple Myeloma in France (2017–2030)

Table 24: Total Symptomatic Cases of Multiple Myeloma in France (2017–2030)

Table 25: Gender-specific cases of Multiple Myeloma in France (2017–2030)

Table 26: Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017–2030)

Table 27: Cases of Multiple Myeloma by Treatment Line in France (2017–2030)

Table 28: Total Incident Cases of Multiple Myeloma in Italy (2017–2030)

Table 29: Total Symptomatic Cases of Multiple Myeloma in Italy (2017–2030)

Table 30: Gender-specific cases of Multiple Myeloma in Italy (2017–2030)

Table 31: Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017–2030)

Table 32: Cases of Multiple Myeloma by Treatment Line in Italy (2017–2030)

Table 33: Total Incident Cases of Multiple Myeloma in Spain (2017–2030)

Table 34: Total Symptomatic Cases of Multiple Myeloma in Spain (2017–2030)

Table 35: Gender-specific cases of Multiple Myeloma in Spain (2017–2030)

Table 36: Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017–2030)

Table 37: Cases of Multiple Myeloma by Treatment Line in Spain (2017–2030)

Table 38: Total Incident Cases of Multiple Myeloma in the United Kingdom (2017–2030)

Table 39: Total Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017–2030)

Table 40: Gender-specific cases of Multiple Myeloma in the United Kingdom (2017–2030)

Table 41: Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017–2030)

Table 42: Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017–2030)

Table 43: Total Incident Cases of Multiple Myeloma in Japan (2017–2030)

Table 44: Total Symptomatic Cases of Multiple Myeloma in Japan (2017–2030)

Table 45: Gender-specific cases of Multiple Myeloma in Japan (2017–2030)

Table 46: Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017–2030)

Table 47: Cases of Multiple Myeloma by Treatment Line in Japan (2017–2030)

Table 48: Total Incident Cases of Multiple Myeloma in China (2017–2030)

Table 49: Total Symptomatic Cases of Multiple Myeloma in China (2017–2030)

Table 50: Gender-specific cases of Multiple Myeloma in China (2017–2030)

Table 51: Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017–2030)

Table 52: Cases of Multiple Myeloma by Treatment Line in China (2017–2030)

Table 53: Belantamab mafodotin, Clinical Trial Description, 2021

Table 54: Idecabtagene vicleucel (bb2121/ ide-cel), Clinical Trial Description, 2021

Table 55: Melflufen, Clinical Trial Description, 2021

Table 56: Farydak (Panobinostat), Clinical Trial Description, 2021

Table 57: Carfilzomib (Kyprolis), Clinical Trial Description, 2021

Table 58: Ninlaro (Ixazomib), Clinical Trial Description, 2021

Table 59: Sarclisa, Clinical Trial Description, 2021

Table 60: Selinexor, Clinical Trial Description, 2021

Table 61: Daratumumab, Clinical Trial Description, 2021

Table 62: Elotuzumab, Clinical Trial Description, 2021

Table 63: Pomalyst/Imnovid, Clinical Trial Description, 2021

Table 64: Iberdomide, Clinical Trial Description, 2021

Table 65: Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy, Clinical Trial Description, 2021

Table 66: Encorafenib (LGX818) plus Binimetinib (MEK162), Clinical Trial Description, 2021

Table 67: BL-8040, Clinical Trial Description, 2021

Table 68: GVAX (GM-CSF), Clinical Trial Description, 2021

Table 69: ECT-001, Clinical Trial Description, 2021

Table 70: Teclistamab, JNJ-64007957, Clinical Trial Description, 2021

Table 71: PBCAR269A, Clinical Trial Description, 2021

Table 72: TAK-079, Clinical Trial Description, 2021

Table 73: GBR-1342, Clinical Trial Description, 2021

Table 74: P-BCMA-101, Clinical Trial Description, 2021

Table 75: MP0250, Clinical Trial Description, 2021

Table 76: Chidamide, Clinical Trial Description, 2021

Table 77: Venetoclax (ABT-199), Clinical Trial Description, 2021

Table 78: Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M), Clinical Trial Description, 2021

Table 79: Keytruda, Clinical Trial Description, 2021

Table 80: Cetrelimab (JNJ-63723283), Clinical Trial Description, 2021

Table 81: REGN5458, Clinical Trial Description, 2021

Table 82: Opdivo, Clinical Trial Description, 2021

Table 83: Descartes-11, Clinical Trial Description, 2021

Table 84: Imfinzi (Durvalumab; MEDI4736), Clinical Trial Description, 2021

Table 85: Imbruvica (ibrutinib), Clinical Trial Description, 2021

Table 86: MOR202 (Felzartamab; TJ-202; MOR-03087), Clinical Trial Description, 2021

Table 87: 8MM Market Size of Multiple Myeloma, in USD Million (2017–2030)

Table 88: Market Size of Multiple Myeloma in the 8MM by Therapies, in USD Millions (2017–2030)

Table 89: Total Market size of Multiple Myeloma in the United States, in USD Million (2017–2030)

Table 90: Market Size of Multiple Myeloma in the United States by Therapies, in USD Millions (2017–2030)

Table 91: Total Market size of Multiple Myeloma in Germany, in USD Million (2017–2030)

Table 92: Market Size of Multiple Myeloma in Germany by Therapies, in USD Millions (2017–2030)

Table 93: Total Market size of Multiple Myeloma in France, in USD Million (2017–2030)

Table 94: Market Size of Multiple Myeloma in France by Therapies, in USD Millions (2017–2030)

Table 95: Total Market size of Multiple Myeloma in Italy, in USD Million (2017–2030)

Table 96: Market Size of Multiple Myeloma in Italy by Therapies, in USD Millions (2017–2030)

Table 97: Total Market size of Multiple Myeloma in Spain, in USD Million (2017–2030)

Table 98: Market Size of Multiple Myeloma in Spain by Therapies, in USD Millions (2017–2030)

Table 99: Total Market size of Multiple Myeloma in the United Kingdom, in USD Million (2017–2030)

Table 100: Market Size of Multiple Myeloma in the United Kingdom by Therapies, in USD Millions (2017–2030)

Table 101: Total Market size of Multiple Myeloma in Japan, in USD Million (2017–2030)

Table 102: Market Size of Multiple Myeloma in Japan by Therapies, in USD Millions (2017–2030)

Table 103: Total Market size of Multiple Myeloma in China, in USD Million (2017–2030)

Table 104: Market Size of Multiple Myeloma in China by Therapies, in USD Millions (2017–2030)

Table 105: Product Combinations in Scope

Table 106: Restricted HTA Outcomes

Table 107: HTA outcome of the Second Assessment of Carfilzomib (CLd)

Table 108: Key HTA decisions for MM Therapies

Table 109: IQWIG

Table 110: Drug-Specific Considerations by ICER

Table 111: Medicaid assessment

List of Figures

Figure 1: Interactions of MM tumor cells with the BM microenvironment. Five kinds of cells in the BM microenvironment are depicted, as well as a few of the complex interactions among these cells and MM cells.

Figure 2: Interaction of multiple myeloma cells in their bone marrow milieu

Figure 3: Technological advances in detecting biomarkers in multiple myeloma.

Figure 4: The National Comprehensive Cancer Network (NCCN) recommendations for initial diagnostic workup of patients with suspected MM

Figure 5: Factors influencing the choice of therapy at relapse

Figure 6: Treatment algorithm for Relapsing Refractory Multiple Myeloma

Figure 7: Algorithm on treatment of patients with multiple myeloma

Figure 8: The NCCN Recommendations for follow-up of patients with MM after primary treatment

Figure 9: The NCCN Recommendations for Primary Myeloma Therapy

Figure 10: The NCCN Recommendations for Myeloma Therapy

Figure 11: The NCCN Recommendations for Lenalidomide Maintenance

Figure 12: The NCCN Recommendations for Management of Renal Disease in Patients With MM

Figure 13: Global Heat Map of Multiple Myeloma

Figure 14: Total Incident Cases of Multiple Myeloma in the 8MM (2017–2030)

Figure 15: Symptomatic Cases of Multiple Myeloma in the 8MM (2017–2030)

Figure 16: Gender-specific cases of Multiple Myeloma in the 8MM (2017–2030)

Figure 17: Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017–2030)

Figure 18: Cases of Multiple Myeloma by Treatment Line in the 8MM (2017–2030)

Figure 19: Total Incident Cases of Multiple Myeloma in the United States (2017–2030)

Figure 20: Symptomatic Cases of Multiple Myeloma in the United States (2017–2030)

Figure 21: Gender-specific cases of Multiple Myeloma in the United States (2017–2030)

Figure 22: Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017–2030)

Figure 23: Cases of Multiple Myeloma by Treatment Line in the United States (2017–2030)

Figure 24: Total Incident Cases of Multiple Myeloma in Germany (2017–2030)

Figure 25: Symptomatic Cases of Multiple Myeloma in Germany (2017–2030)

Figure 26: Gender-specific cases of Multiple Myeloma in Germany (2017–2030)

Figure 27: Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017–2030)

Figure 28: Cases of Multiple Myeloma by Treatment Line in Germany (2017–2030)

Figure 29: Total Incident Cases of Multiple Myeloma in France (2017–2030)

Figure 30: Symptomatic Cases of Multiple Myeloma in France (2017–2030)

Figure 31: Gender-specific cases of Multiple Myeloma in France (2017–2030)

Figure 32: Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017–2030)

Figure 33: Cases of Multiple Myeloma by Treatment Line in France (2017–2030)

Figure 34: Total Incident Cases of Multiple Myeloma in Italy (2017–2030)

Figure 35: Symptomatic Cases of Multiple Myeloma in Italy (2017–2030)

Figure 36: Gender-specific cases of Multiple Myeloma in Italy (2017–2030)

Figure 37: Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017–2030)

Figure 38: Cases of Multiple Myeloma by Treatment Line in Italy (2017–2030)

Figure 39: Total Incident Cases of Multiple Myeloma in Spain (2017–2030)

Figure 40: Symptomatic Cases of Multiple Myeloma in Spain (2017–2030)

Figure 41: Gender-specific cases of Multiple Myeloma in Spain (2017–2030)

Figure 42: Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017–2030)

Figure 43: Cases of Multiple Myeloma by Treatment Line in Spain (2017–2030)

Figure 44: Total Incident Cases of Multiple Myeloma in the United Kingdom (2017–2030)

Figure 45: Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017–2030)

Figure 46: Gender-specific cases of Multiple Myeloma in the United Kingdom (2017–2030)

Figure 47: Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017–2030)

Figure 48: Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017–2030)

Figure 49: Total Incident Cases of Multiple Myeloma in Japan (2017–2030)

Figure 50: Symptomatic Cases of Multiple Myeloma in Japan (2017–2030)

Figure 51: Gender-specific cases of Multiple Myeloma in Japan (2017–2030)

Figure 52: Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017–2030)

Figure 53: Cases of Multiple Myeloma by Treatment Line in Japan (2017–2030)

Figure 54: Total Incident Cases of Multiple Myeloma in China (2017–2030)

Figure 55: Symptomatic Cases of Multiple Myeloma in China (2017–2030)

Figure 56: Gender-specific cases of Multiple Myeloma in China (2017–2030)

Figure 57: Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017–2030)

Figure 58: Cases of Multiple Myeloma by Treatment Line in China (2017–2030)

Figure 59: GBR 1342 BEAT Design and Redirected Lysis

Figure 60: Mechanism of action of MP0250

Figure 61: Mechanism of action of Chidamide

Figure 62: Total Market Size of Multiple Myeloma in the 8MM, in USD Millions (2017–2030)

Figure 63: Market Size of Multiple Myeloma in the 8MM by Therapies, in USD Millions (2017–2030)

Figure 64: Market Size of Multiple Myeloma in the United States by Therapies, in USD Millions (2017–2030)

Figure 65: Market Size of Multiple Myeloma in Germany by Therapies, in USD Millions (2017–2030)

Figure 66: Market Size of Multiple Myeloma in France by Therapies, in USD Millions (2017–2030)

Figure 67: Market Size of Multiple Myeloma in Italy by Therapies, in USD Millions (2017–2030)

Figure 68: Market Size of Multiple Myeloma in Spain by Therapies, in USD Millions (2017–2030)

Figure 69: Market Size of Multiple Myeloma in the United Kingdom by Therapies, in USD Millions (2017–2030)

Figure 70: Market Size of Multiple Myeloma in Japan by Therapies, in USD Millions (2017–2030)

Figure 71: Market Size of Multiple Myeloma in China by Therapies, in USD Millions (2017–2030)

Figure 72: Comparison of HTA recommendations across triplet therapies

Figure 73: Time from EMA MA to First Accepted or Restricted HTA Outcome

Figure 74: Comparative availability over time of ixazomib for new patients with relapsed or refractory multiple myeloma between France and England and main milestones of the appraisal.

• GlaxoSmithKline

• Bristol-Myers Squibb/Bluebird bio

• Oncopeptides AB

• Secura Bio

• Amgen (Onyx therapeutics)

• Takeda Pharmaceutical (Millennium Pharmaceuticals)

• Sanofi

• Karyopharm Therapeutics

• Janssen Biotech

• Bristol Myers Squibb/AbbVie

• Takeda Pharmaceutical/Janssen Pharmaceutical

• Bristol-Myers Squibb Company (Celgene)

• Celgene (BMS)

• Bristol-Myers Squibb/Celgene

• RAPA Therapeutics

• Pfizer (Array Biopharma)

• Cellectar Biosciences

• BioLineRx

• Celgene/Aduro Biotech

• ExCellThera

• Janssen Pharmaceutical

• Precision BioSciences

• Takeda

• Glenmark (Ichnos Sciences SA)

• Poseida Therapeutics

• Molecular Partners AG

• Chipscreen Biosciences

• AbbVie/Genentech (Roche)

• Janssen Biotech/Nanjing Legend Biotech

• Merck Sharp & Dohme Corp.

• Janssen

• Regeneron Pharmaceuticals

• Bristol-Myers Squibb

• Cartesian Therapeutics

• AstraZeneca

• Abbvie (Pharmacyclics) and Johnson & Johnson

• MorphoSys AG/I-Mab Biopharma

  • Tags:
  • Multiple Myeloma
  • Multiple Myeloma market
  • Multiple Myeloma market research
  • Multiple Myeloma market insight
  • Multiple Myeloma market trends
  • Multiple Myeloma market forecast
  • Multiple Myeloma market share
  • Multiple Myeloma pipeline drugs
  • Multiple Myeloma treatment algorit...
  • Multiple Myeloma drugs
  • Multiple Myeloma sales forecasting
  • Multiple Myeloma market size
  • Multiple Myeloma disease
  • Multiple Myeloma epidemiology
  • Multiple Myeloma

Forward to Friend

Need A Quote